contact
Профессиональная косметика и материалы для эстетической медицины

Совершать покупки могут только салоны красоты и дипломированные специалисты

Бесплатный номер

8-800-700 33 62

Ежедневно с 7 до 18 ч (сб-вс с 8 до 16) время московское
Ваша корзина
Корзина пуста!

Осветляющие средства для кожи. Литература

Список использованной литературы:

  1. Callender VD, St Surin-Lord S, Davis EC, et al. Postinflammatory hyperpigmentation: etiologic and therapeutic considerations. Am J Clin Dermatol. 2011;12:87-99.
  2. Haider RM, Richards GM. Management of dyschromias in ethnic skin. Dermatol Ther. 2004;17:151-157.
  3. Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80: 387-394.
  4. Draelos Z. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther. 2007;20:308-313.
  5. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cuian Med Surg. 2009;28:77-85.
  6. Sheth VM, Pandya AG. Melasma: a comprehensive update: part 11. J Am Acad Dermatol. 2011;65:699-714; quiz 715.
  7. Glenn M, Grimes P, Pitt E, et al. Evaluation of clinical and light microscopic effects of various concentrations of hydroquinone. Clin Res. 1991;39:83A.
  8. Skin bleaching drug products for over-the-counter human use; proposed rule. Fed Regist. 2006;71(167):51146-51155. To be codified at 21 CFR §310.
  9. Kramer KE, Lopez A, Stefanato CM, et al. Exogenous ochronosis. J Am Acad Dermatol. 2000;42(5, pt 2):869-871.
  10. Olumide Y, Akinkugbe A, Altraide D, et al. Complications of chronic use of skin lightening cosmetics. Int J Dermatol. 2008;47:344-353.
  11. Grimes PE. Melasma: etiologic and therapeutic considerations. Arch Dermatol. 1995;131:1453-1457.
  12. Levitt J. The safety of hydroquinone: a dermatologist’s response to the 2006 Federal Register [published online ahead of print April 27, 2007). J Am Acad Dermatol. 2007;57:854-872.
  13. Friedlander BR, Heame FT, Newman BJ. Mortality, cancer incidence, and sickness-absence in photographic predecessors: an epidemiologic study. J Occup Med. 1982;24:605-613.
  14. Nordlund J, Grimes P, Ortonne JP The safety of hydroquinone. J Cosmet Dermatol. 2006;5:168-169.
  15. Regev L, Wu M, Zlotolow R, et al. Hydroquinone, a benzene metabolite, and leukemia: a case report and review of the literature [published online ahead of print April 21,2011]. Toxicol Ind Health. 2012;28:64-73.
  16. Makropoulous V, Alexopoulos EC. Case report: hydroquinone and/ or glutaraldehyde induced acute myeloid leukaemia? J Occup Med Toxicol. 2006; 1:19.
  17. Ly F, Kane A, Deme A, et al. First cases of squamous cell carcinoma associated with cosmetic use of bleaching compounds [published online ahead of print January 12, 2010], Ann Dermatol Venereol. 2010;137:128-131.
  18. Dar NR, Shaheen, Mustafvi SA, et al. Cutaneous pseudolymphoma due to topical application of 4% hydroquinone cream for melasma. J Coll Physicians Surg Pak. 2005;15:496-497.
  19. Draelos ZD. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin effectively improves the appearance of solar lentigines in ethnic groups. J Cosmet Dermatol. 2006;5: 239-244.
  20. Fleischer AB Jr, Schwartzel EH, Colby SI, et al. The combination of 2% 4-hydroxyanisole (mequinol) and 0.01% tretinoin is effective in improving the appearance of solar lentigines and related hyper-pigmented lesions in two double-blind multicenter clinical studies. J Am Acad Dermatol. 2000;42:459-467.
  21. Ortonne JP, Camacho F, Wainwright N, et al. Safety and efficacy of combined use of 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% solution and sunscreen in solar lentigines. Cutis. 2004;74:261-264.
  22. Callender VD. A small open-label study of a 2% 4-hydroxyanisole and 0.01% tretinoin solution for the treatment of postinflammatory hyperpigmentation. J Am Acad Dermatol. 2004;50(suppl 3):P175.
  23. Taylor SC, Callender VD. A multicenter, 12-week, phase 3b trial: a combination solution of mequinol 2%/tretinoin 0.01% vs hydroquinone 4% cream in the treatment of mild to moderate postinflammatory hyperpigmentation (abstract). J Am Acad Dermatol. 2006;54(suppl 3):AB194.
  24. Jarratt M. Mequinol 2%/tnetinoin 0.01% solution: an effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Clifts. 2004;74:319-322.
  25. Piacquadio D, Farris P, Downie J, et al. Mequinol 2%/tretinoin 0.01% solution monotherapy and combination treatment of solar lentigines and postinflammatory hyperpigmentation. J Am Acad Dermatol. 2004;52(suppl 3):P145.
  26. Yoshimura K, Tsukamoto K, Okazaki M, et al. Effects of all-trans retinoic acid on melanogenesis in pigmented skin equivalents and monolayer culture of melanocytes. J Dermatol Sci. 2001 ;27 (suppl 1):S68-S75.
  27. Kasraee B, Fallahi MR, Ardekani GS, et al. Retinoic acid synergis-tically enhances the melanocytotoxic and depigmenting effects of monobenzylether of hydroquinone in black guinea pig skin. Exp Dermatol. 2006;15:509-514.
  28. Bulengo-Ransby SM, Griffiths CE, Kimbrough-Green CK, et al. Topical tretinoin (retinoic acid) therapy for hyperpigmented lesions caused by inflammation of the skin in black patients. N Engl J Med. 1993;328:1438-1443.
  29. Jacyk WK, Mpofu P. Adapalene gel 0.1% for topical treatment of acne vulgaris in African patients. Cutis. 2001;68(suppl 4):48-54.
  30. Grimes P, Callender V. Tazarotene cream for postinflammatory hyperpigmentation and acne vulgaris in darker skin: a doubleblind, randomized, vehicle-controlled study. Cutis. 2006; 77:45-50.
  31. Fitton LA, Davidson M, Moore KJ, et al. The liver/erythrocyte pyruvate kinase gene complex (Pk-1) in the mouse: regulatory gene mutations. Genet Res. 1991;58:233-241.
  32. Balina LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol. 1991;30:893-895.
  33. Lowe NJ, Rizk D, Grimes P, et al. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20:945-959.
  34. Kakita LS, Lowe NJ. Azelaic acid and glycolic acid combination therapy for facial hyperpigmentation in darker-skinned patients: a clinical comparison with hydroquinone. Clin Ther. 1998;20:960-970.
  35. Sarkar R, Bhalla M, Kanwar AJ. A comparative study of 20% azelaic acid cream monotherapy versus a sequential therapy in the treatment of melasma in dark-skinned patients. Dermatology. 2002;205:249-254.
  36. Kligman AM, Willis 1. A new formula for depigmenting human skin. Arch Dermatol. 1975;111:40-48.
  37. Ruiz-Maldonado R, Orozco-Covarrubaid ML. Post-inflammatory hypopigmentation and hyperpigmentation. Semin Cutan Med Surg. 1997;16:36-43.
  38. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3:20-31.
  39. Cook-Bolden FE, Hamilton SF. An open-label study of the efficacy and tolerability of microencapsulated hydroquinone 4% and retinol 0.15% with antioxidants for the treatment of hyperpigmentation. Ciifis. 2008;81:365-371.
  40. Grimes PE, Bhawan J, Guevara 1L, et al. Continuous therapy followed by a maintenance therapy regimen with a triple combination cream for melasma (published online ahead of print April 15, 2010). J Am Acad Dermatol. 2010;62:962-967.
  41. Taylor SC, Torok H, Jones T, et al. Efficacy and safety of a new triple-combination agent for the treatment of facial melasma. Cutis. 2003;72:67-72.
  42. Ho ET, Trookman NS, Sperber BR, et al. A randomized, doubleblind, controlled comparative trial of the anti-aging properties of non-prescription tri-retinol 1.1% vs. prescription tretinoin 0.025% J Drugs Dermatol. 2012;11:64-69.
  43. Maeda K, Fukuda M. Arbutin: mechanism of its depigmenting action in human melanocyte culture. J Pharmacol Exp Ther. 1996; 276:765-769.
  44. Funayama M, Arakawa H, Yamamoto R, et al. Effects of a- and P-arbutin on activity of tyrosinases from mushroom and mouse melanoma. Biosci Biotechnol Biochem. 1995;59:143-144.
  45. Hamed SH, Sriwiriyanont P, deLong MA, et al. Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent. J Cosmet Sci. 2006;57:291-308.
  46. Boissy RE, Visscher M, DeLong MA. Deoxyarbutin: a novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol. 2005;14:601-608.
  47. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg. 1996;22:443-447.
  48. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg. 1999;25:282-284.
  49. Serra-Baldrich E, Tribo MJ, Camarasa JG. Allergic contact dermatitis from kojic acid. Contact Dermatitis. 1998;39:86-87.
  50. Nakagavva M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis. 1995;32:9-13.
  51. Petit L, Pierard GE. Skin-lightening products revisited. Ini J Cosmet Sci. 2003;25:169-181.
  52. Draelos ZD, Yatskayer M, Bhushan P, et al. Evaluation of a kojic acid, emblica extract, and glycolic acid formulation compared with hydroquinone 4% for skin lightening. Cutis. 2010;86:153-158.
  53. Amer M, Metwalh M. Topical liquiritin improves melasma. Int J Dermatol. 2000;39:299-301.
  54. Fu B, Li H, Wang X, et al. Isolation and identification of ftavonoids in licorice and a study of their inhibitory effects on tyrosinase. J Agric Food Chem. 2005;53:7408-7414.
  55. Yokota T, Nishio H, Kubota Y, et al. The inhibitory effect of gla-bridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res. 1998;11:355-361.
  56. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP A doubleblind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43:604-607.
  57. Farris PK. Topical vitamin C: a useful agent for treating photoaging and other dermatologic conditions. Dermatol Surg. 2005;31 (7, pt 2):814-817; discussion 818.
  58. Choi YK, Rho YK, Yoo KH, et al. Effects of vitamin C vs. multivitamin on melanogenesis: comparative study in vitro and in vivo. Int J Dermatol. 2010;49:218-226.
  59. Finkey MB, Herndon J, Thomas S, et al. Soy moisturizer SPF15 improves dyschromia. J Am Acad Dermatol. 2005;52(suppl):P170.
  60. Paine C, Sharlow E, Liebel F, et al. An alternative approach to depigmentation by soybean extracts via inhibition of the PAR-2 pathway. J Invest Dermatol. 2001;116:587-595.
  61. Seiberg M, Paine C, Sharlow E, et al. The protease-activated receptor 2 regulates pigmentation via keratinocyte-melanocyte interactions. Exp Cell Res. 2000;254:25-32.
  62. Baumann L, Rodriguez D, Taylor SC, et al. Natural considerations for skin of color. Cutis. 2006;78(suppl 6):2-19.
  63. Wallo W, Nebus J, Leyden JJ. Efficacy of a soy moisturizer in photoaging: a double-blind, vehicle-controlled, 12-week study. J Drugs Dermatol. 2007;6:917-922.
  64. Hermanns JF, Petit L, Pierard-Franchimont C, et al. Assessment of topical hypopigmenting agents on solar lentigines of Asian women. Dermatology'. 2002;204:281-286.
  65. Sah A, Stephens TJ, Kurtz ES. Topical acne treatment improves postacne postinflammatory hyperpigmentation (PIH) in skin of color. J Am Acad Dermatol. 2005;52(suppl):P25.
  66. Choi S, Lee SK, Kim JE, et al. Aloesin inhibits hyperpigmentation induced by UV radiation. Clin Exp Dermatol. 2002;27: 513-515.
  67. Jones K, Hughes J, Hong M, et al. Modulation of melanogenesis by aloesin: a competitive inhibitor of tyrosinase. Pigment Cell Res. 2002;15:335-340.
  68. Wang Z, Li X, Yang Z, et al. Effects of aloesin on melanogenesis in pigmented skin equivalents. Int J Cosmet Sci. 2008;30:121-130.
  69. Hakozaki T, Minwalla L, Zhuang J, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol. 2002;147:20-31.
  70. Kimball AB, Kaczvinsky JR, Li J, et al. Reduction in the appearance of facial hyperpigmentation after use of moisturizers with a combination of topical niacinamide and N-acetyl glucosamine: results of a randomized, double-blind, vehicle-controlled trial (published online ahead of print August 28, 2009]. BrJ Dermatol. 2010;162:435-441.
  71. Bissett DL. Glucosamine: an ingredient with skin and other benefits. J Cosmet Dermatol. 2006;5:309-315.
  72. Bissett DL, Robinson L, Li J, et al. Topical N-acetyl glucosamine reduces the appearance of hyperpigmented spots on human facial skin. Poster presented at: 64th Annual Meeting of the American Academy of Dermatology; March 3-7,2006; San Francisco, CA. P236. 



Расскажите друзьям и коллегам:


Комментарии

Зарегистрируйтесь, чтобы получить возможность оставлять комментарии.

К этой статье еще не оставили комментариев.